[Polyarthritis flare in patient with ankylosing spondylitis treated with infliximab].
Over the last ten years, the treatment of seronegative spondyloarthropathies has changed dramatically with the introduction of the anti-tumor necrosis factor alpha (TNFα) agents. Nevertheless, there is a growing number of studies describing several adverse reactions in patients treated with biological agents. In the present report we describe the case of a 22-year-old male patient with ankylosing spondylitis who developed a "paradoxic" adverse reaction, while receiving infliximab.
Clinica Reumatologica, Università Politecnica delle Marche, Ospedale A. Murri, Jesi (AN), Italia. dr.gmarwin@gmail.com
M
M
Gutierrez
A
A
Becciolini
C
C
Bertolazzi
L
L
Di Geso
M
M
Tardella
A
A
Ariani
E
E
Filippucci
W
W
Grassi
D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D001168:Arthritis / Q000097:blood / Q000139:chemically induced*; D005334:Fever / Q000139:chemically induced; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D000069285:Infliximab; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage / Q000627:therapeutic use; D013167:Spondylitis, Ankylosing / Q000097:blood / Q000188:drug therapy*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*; D055815:Young Adult
D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D008727:Methotrexate